Genmab As Stock Today
| GMAB Stock | USD 28.70 0.37 1.31% |
Performance2 of 100
| Odds Of DistressLess than 1
|
Genmab AS is trading at 28.70 as of the 23rd of April 2024, a 1.31 percent up since the beginning of the trading day. The stock's open price was 28.33. Genmab AS has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Genmab AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of June 2023 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of June 2009 | Category Healthcare | Classification Health Care |
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on NASDAQ Exchange in the United States. The company has 649.93 M outstanding shares of which 2.4 M shares are currently shorted by private and institutional investors with about 4.05 trading days to cover. More on Genmab AS
Moving together with Genmab Stock
| 0.62 | OPT | Opthea | PairCorr |
| 0.65 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 8th of May 2024
Genmab Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genmab AS's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genmab AS or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Mats Pettersson | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cash Cows (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, OMX Copenhagen All, ARCA Biotechnology, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Cash Cows, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Genmab AS report their recommendations after researching Genmab AS's financial statements, talking to executives and customers, or listening in on Genmab AS's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Genmab AS. The Genmab consensus assessment is calculated by taking the average forecast from all of the analysts covering Genmab AS. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Genmab AS's liquidity, profitability, solvency, and operating efficiency, Genmab AS is performing exceptionally good at this time. It has a great odds to report excellent financial results in May. Financial strength of Genmab AS is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Genmab AS's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Genmab AS's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Genmab AS's financial leverage. It provides some insight into what part of Genmab AS's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Genmab AS (GMAB) is traded on NASDAQ Exchange in USA. It is located in Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 and employs 2,204 people. Genmab AS is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 18.65 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab AS's market, we take the total number of its shares issued and multiply it by Genmab AS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genmab AS conducts business under Biotechnology sector and is part of Health Care industry. The entity has 649.93 M outstanding shares of which 2.4 M shares are currently shorted by private and institutional investors with about 4.05 trading days to cover.
Genmab AS currently holds about 21.61 B in cash with 7.38 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 33.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Genmab AS Probability Of Bankruptcy
Ownership AllocationGenmab AS has a total of 649.93 Million outstanding shares. Roughly 93.0 (percent) of Genmab AS outstanding shares are held by general public with 0.00699999999999999 % owned by insiders and only 7.22 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genmab Ownership Details
Genmab Stock Price Odds Analysis
What are Genmab AS's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Genmab AS jumping above the current price in 90 days from now is about 62.58%. The Genmab AS probability density function shows the probability of Genmab AS stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Genmab AS has a beta of 0.9947. This usually indicates Genmab AS market returns are sensitive to returns on the market. As the market goes up or down, Genmab AS is expected to follow. Additionally, genmab AS has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Genmab AS to move above the current price in 90 days from now is about 62.58 (This Genmab AS probability density function shows the probability of Genmab Stock to fall within a particular range of prices over 90 days) .
Genmab Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Genmab AS that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Genmab AS's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Genmab AS's value.| Instituion | Recorded On | Shares | |
| Stifel Financial Corp | 2023-12-31 | 672.9 K | |
| Royal Bank Of Canada | 2023-12-31 | 641 K | |
| Wells Fargo & Co | 2023-12-31 | 557.1 K | |
| Northern Trust Corp | 2023-12-31 | 539 K | |
| Millennium Management Llc | 2023-12-31 | 512.3 K | |
| Hardman Johnston Global Advisors Llc | 2023-12-31 | 482.7 K | |
| American Century Companies Inc | 2023-12-31 | 456.4 K | |
| Point72 Asset Management, L.p. | 2023-09-30 | 278.6 K | |
| Fmr Inc | 2023-12-31 | 267.5 K | |
| Alliancebernstein L.p. | 2023-12-31 | 15.6 M | |
| Blackrock Inc | 2023-12-31 | 4.4 M |
Genmab AS Historical Income Statement
Genmab AS Income Statement is one of the three primary financial statements used for reporting Genmab's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Genmab AS revenue and expense. Genmab AS Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Genmab AS's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 3.5 B, whereas Interest Expense is forecasted to decline to about 16.6 M. View More FundamentalsGenmab Stock Against Markets
Picking the right benchmark for Genmab AS stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Genmab AS stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Genmab AS is critical whether you are bullish or bearish towards Genmab AS at a given time. Please also check how Genmab AS's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genmab AS without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Genmab AS Corporate Directors
Genmab AS corporate directors refer to members of a Genmab AS board of directors. The board of directors generally takes responsibility for the Genmab AS's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Genmab AS's board members must vote for the resolution. The Genmab AS board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Takahiro Hamatani | Senior Director | Profile | |
| Daniel Bruno | Director, Employee Representative | Profile | |
| Peter Kristensen | Director, Employee Representative | Profile | |
| Paolo Paoletti | Independent Director | Profile |
How to buy Genmab Stock?
Before investing in Genmab AS, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Genmab AS. To buy Genmab AS stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Genmab AS. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Genmab AS stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Genmab AS stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Genmab AS stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Genmab AS, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Genmab Stock please use our How to Invest in Genmab AS guide.
Already Invested in Genmab AS?
The danger of trading Genmab AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Genmab AS is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Genmab AS. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Genmab AS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.Note that the Genmab AS information on this page should be used as a complementary analysis to other Genmab AS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Genmab AS's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.246 | Earnings Share 0.94 | Revenue Per Share 25.2244 | Quarterly Revenue Growth (0.09) | Return On Assets 0.1017 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.